Cargando…

Real-world pharmacological treatment of patients with postpartum depression in China from 2016 to 2020: A cross-sectional analysis

OBJECTIVE: To determine the use and tendency of drugs for postpartum depression (PPD) in nine cities across China in 2016–2020 in order to provide a reference for drug use in the clinic. METHODS: The prescription data of drugs for PPD outpatients in nine cities (Beijing, Chengdu, Guangzhou, Harbin,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Kai, Wang, Xianli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649344/
https://www.ncbi.nlm.nih.gov/pubmed/36387336
http://dx.doi.org/10.1016/j.jsps.2022.07.002
_version_ 1784827776583335936
author Sun, Kai
Wang, Xianli
author_facet Sun, Kai
Wang, Xianli
author_sort Sun, Kai
collection PubMed
description OBJECTIVE: To determine the use and tendency of drugs for postpartum depression (PPD) in nine cities across China in 2016–2020 in order to provide a reference for drug use in the clinic. METHODS: The prescription data of drugs for PPD outpatients in nine cities (Beijing, Chengdu, Guangzhou, Harbin, Hangzhou, Shanghai, Shenyang, Tianjin and Zhengzhou) across China in 2016–2020 were extracted from the Hospital Prescription Analysis Cooperation Project database of the Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association. A cross-sectional analysis was then conducted of patient age, total prescription quantity, average prescription amount, defined daily doses (DDDs) of drugs, defined daily cost (DDC) of drugs and so on. RESULTS: In 2016–2020, more than half of PPD patients in these nine cities were distributed in first-tier cities (Beijing, Shanghai and Guangzhou), and were mainly aged 30–39 years. During the five-year period, the prescription quantity, total prescription amount and average prescription amount increased by 20.95%, 35.41% and 11.02%, respectively. In terms of prescription frequency and prescription amount, selective serotonin reuptake inhibitors (SSRIs) ranked first, followed by serotonin-norepinephrine reuptake inhibitors (SNRIs). With regard to DDDs, escitalopram, sertraline, paroxetine and venlafaxine ranked high, and sertraline was top year by year. The DDC of vortioxetine and milnacipran was greatest, while that of escitalopram, olanzapine and quetiapine declined sharply after being included in the China centralized drug-procurement program. CONCLUSION: The number of PPD patients and the total prescription amount in the nine cities across China increased in 2016–2020. SSRIs and SNRIs were the main drugs for PPD treatment. Due to the national centralized drug-procurement policy, there has been a great reduction in the DDC, lightening the economic burden on patients.
format Online
Article
Text
id pubmed-9649344
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-96493442022-11-15 Real-world pharmacological treatment of patients with postpartum depression in China from 2016 to 2020: A cross-sectional analysis Sun, Kai Wang, Xianli Saudi Pharm J Original Article OBJECTIVE: To determine the use and tendency of drugs for postpartum depression (PPD) in nine cities across China in 2016–2020 in order to provide a reference for drug use in the clinic. METHODS: The prescription data of drugs for PPD outpatients in nine cities (Beijing, Chengdu, Guangzhou, Harbin, Hangzhou, Shanghai, Shenyang, Tianjin and Zhengzhou) across China in 2016–2020 were extracted from the Hospital Prescription Analysis Cooperation Project database of the Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association. A cross-sectional analysis was then conducted of patient age, total prescription quantity, average prescription amount, defined daily doses (DDDs) of drugs, defined daily cost (DDC) of drugs and so on. RESULTS: In 2016–2020, more than half of PPD patients in these nine cities were distributed in first-tier cities (Beijing, Shanghai and Guangzhou), and were mainly aged 30–39 years. During the five-year period, the prescription quantity, total prescription amount and average prescription amount increased by 20.95%, 35.41% and 11.02%, respectively. In terms of prescription frequency and prescription amount, selective serotonin reuptake inhibitors (SSRIs) ranked first, followed by serotonin-norepinephrine reuptake inhibitors (SNRIs). With regard to DDDs, escitalopram, sertraline, paroxetine and venlafaxine ranked high, and sertraline was top year by year. The DDC of vortioxetine and milnacipran was greatest, while that of escitalopram, olanzapine and quetiapine declined sharply after being included in the China centralized drug-procurement program. CONCLUSION: The number of PPD patients and the total prescription amount in the nine cities across China increased in 2016–2020. SSRIs and SNRIs were the main drugs for PPD treatment. Due to the national centralized drug-procurement policy, there has been a great reduction in the DDC, lightening the economic burden on patients. Elsevier 2022-10 2022-07-19 /pmc/articles/PMC9649344/ /pubmed/36387336 http://dx.doi.org/10.1016/j.jsps.2022.07.002 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Sun, Kai
Wang, Xianli
Real-world pharmacological treatment of patients with postpartum depression in China from 2016 to 2020: A cross-sectional analysis
title Real-world pharmacological treatment of patients with postpartum depression in China from 2016 to 2020: A cross-sectional analysis
title_full Real-world pharmacological treatment of patients with postpartum depression in China from 2016 to 2020: A cross-sectional analysis
title_fullStr Real-world pharmacological treatment of patients with postpartum depression in China from 2016 to 2020: A cross-sectional analysis
title_full_unstemmed Real-world pharmacological treatment of patients with postpartum depression in China from 2016 to 2020: A cross-sectional analysis
title_short Real-world pharmacological treatment of patients with postpartum depression in China from 2016 to 2020: A cross-sectional analysis
title_sort real-world pharmacological treatment of patients with postpartum depression in china from 2016 to 2020: a cross-sectional analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649344/
https://www.ncbi.nlm.nih.gov/pubmed/36387336
http://dx.doi.org/10.1016/j.jsps.2022.07.002
work_keys_str_mv AT sunkai realworldpharmacologicaltreatmentofpatientswithpostpartumdepressioninchinafrom2016to2020acrosssectionalanalysis
AT wangxianli realworldpharmacologicaltreatmentofpatientswithpostpartumdepressioninchinafrom2016to2020acrosssectionalanalysis